The atrial fibrillation system could transform how common cardiac arrhythmia is managed. Credit: Nakharin T / Shutterstock. Canadian Medical solutions company Kardium has secured $104m in a financing round for its Globe mapping and ablation system, which is designed to treat atrial fibrillation.
Existing investor Fidelity Management & Research Company led the funding round with additional funds from T Rowe Price Associates and T Rowe Price Investment Management, along with new investor Durable Capital Partners. Kardium’s Globe mapping and ablation system is poised to transform how common cardiac arrhythmia is managed. The system comprises a single catheter, equipped with a 122-electrode array and advanced software, enabling rapid pulmonary vein isolation, high-definition mapping and atrial ablation.
This investment will enable Kardium to complete its PULSAR clinical study of the system, aimed at securing regulatory approvals. Kardium will also use the funding to bolster its production team and capacity and establish a clinical support and commercial team to prepare for launching the Globe system commercially. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. View profiles in store Company Profile – free sample Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, .
